Gritstone bio, Inc. (GRTS)

0.9627 +0.0927 (+10.66%) 收市：04:00PM EDT

Gritstone bio, Inc.

5959 Horton Street
Suite 300
EmeryVille, CA 94608
United States
510 871 6100
https://gritstonebio.com

版塊: Healthcare
行業: Biotechnology
全職員工: 231

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Andrew R. Allen BCh, BM, M.D., MA, MRCP, Ph.D.	Co-Founder, President, CEO & Director	1.01M	無	1966
Mr. Erin E. Jones M.S.	Executive VP & COO	689.87k	無	1972
Dr. Karin Jooss Ph.D.	Executive VP and Head of Research & Development	748.2k	無	1965
Ms. Vassiliki Economides	Executive VP & CFO	無	無	1981
Mr. James Cho	Chief Accounting Officer	無	無	無
George MacDougall	Director of Investor Relations & Corporate Communications	無	無	無
Ms. Stacy Proctor	Executive VP & Chief People Officer	無	無	無
Dr. Matthew J. Hawryluk M.B.A., Ph.D.	Executive VP & Chief Business Officer	無	無	1978

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

公司管治

截至 2024年5月1日 止，Gritstone bio, Inc. 的 ISS 管治質素評分為 7。 Pillar 分數正在審核中：7；董事會：3；股東權利：8；現金賠償：9。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。